Alvimopan for the management of postoperative ileus
- PMID: 16076918
- DOI: 10.1345/aph.1E615
Alvimopan for the management of postoperative ileus
Abstract
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, safety, dosage, and administration of alvimopan, a peripherally acting mu-opioid receptor antagonist, in the management of postoperative ileus (POI).
Data sources: A literature search (1980-October 2004) applying the terms alvimopan, ADL 8-2698, and LY246736 was conducted using MEDLINE. Information was also obtained from scientific congress abstracts and data on file with the manufacturer.
Study selection and data extraction: Studies and abstracts investigating alvimopan and POI were considered for inclusion; however, they were restricted to English-language articles.
Data synthesis: Alvimopan is a novel, peripherally acting mu-opioid receptor antagonist that is currently under evaluation for the management of POI. POI presents significant clinical challenges that can delay patient recovery and contribute to increased morbidity and prolonged hospitalization after surgery. Clinical trials have demonstrated that alvimopan, at oral doses of 6 and 12 mg, can accelerate time to recovery of gastrointestinal (GI) function and time to hospital discharge following abdominal surgery. The incidence of adverse events with alvimopan therapy was shown to be similar to that of placebo.
Conclusions: Alvimopan is well tolerated and effective at accelerating GI recovery and time to discharge in patients who have undergone bowel resection or hysterectomy when administered prior to surgery and twice daily thereafter until discharge or for up to 7 days. Alvimopan potentially offers significant benefits for patients with POI over currently available treatments.
Similar articles
-
Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection.J Am Coll Surg. 2007 Apr;204(4):609-16. doi: 10.1016/j.jamcollsurg.2007.01.041. J Am Coll Surg. 2007. PMID: 17382220 Clinical Trial.
-
Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.Dis Colon Rectum. 2005 Jun;48(6):1114-25; discussion 1125-6; author reply 1127-9. doi: 10.1007/s10350-005-0035-7. Dis Colon Rectum. 2005. PMID: 15906123 Clinical Trial.
-
Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.Ann Surg. 2004 Oct;240(4):728-34; discussion 734-5. doi: 10.1097/01.sla.0000141158.27977.66. Ann Surg. 2004. PMID: 15383800 Free PMC article. Clinical Trial.
-
Alvimopan for postoperative ileus.Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. doi: 10.2146/ajhp080445. Am J Health Syst Pharm. 2009. PMID: 19574601 Review.
-
A meta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery.Dis Colon Rectum. 2012 May;55(5):611-20. doi: 10.1097/DCR.0b013e318249fc78. Dis Colon Rectum. 2012. PMID: 22513441 Review.
Cited by
-
Postoperative ileus: strategies for reduction.Ther Clin Risk Manag. 2008 Oct;4(5):913-7. doi: 10.2147/tcrm.s2390. Ther Clin Risk Manag. 2008. PMID: 19209273 Free PMC article.
-
Si-jun-zi decoction treatment promotes the restoration of intestinal function after obstruction by regulating intestinal homeostasis.Evid Based Complement Alternat Med. 2014;2014:928579. doi: 10.1155/2014/928579. Epub 2014 Apr 28. Evid Based Complement Alternat Med. 2014. PMID: 24876882 Free PMC article.
-
Anesthetic Routines: The Anesthesiologist's Role in GI Recovery and Postoperative Ileus.Adv Prev Med. 2011;2011:976904. doi: 10.4061/2011/976904. Epub 2010 Dec 29. Adv Prev Med. 2011. PMID: 21991449 Free PMC article.
-
Incidence and predictors of prolonged postoperative ileus after colorectal surgery in the context of an enhanced recovery pathway.Surg Endosc. 2019 Jul;33(7):2313-2322. doi: 10.1007/s00464-018-6514-4. Epub 2018 Oct 17. Surg Endosc. 2019. PMID: 30334165
-
Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection.P T. 2010 Jan;35(1):44-9. P T. 2010. PMID: 20182561 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials